ASTRAZENECA PLC

AZN · XNYS

CIK 901832fmd_1HNFSF1R12SXGA1SVS3Q0KKERGManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2025, 32 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	23,002	22,465	22,090	24,384	26,617	37,417	44,351	45,811	54,073	58,739
Cost of revenue	4,126	4,318	4,936	4,921	5,299	12,437	12,391	8,268	10,207	10,633
Gross profit	18,876	18,147	17,154	19,463	21,318	24,980	31,960	37,543	43,866	48,106
Research and development	5,890	5,757	5,932	6,059	5,991	9,736	9,762	10,935	13,583	14,232
Selling, general and administrative	9,413	10,233	10,031	11,682	11,294	15,234	18,419	19,216	19,977	19,933
Operating income	4,902	3,677	3,387	2,924	5,162	1,056	3,757	8,193	10,003	13,743
Interest expense	1,384	1,508	1,419	1,432	1,306	1,300	1,346	1,626	1,742	1,694
Income before taxes	3,552	2,227	1,993	1,548	3,916	(265)	2,501	6,899	8,691	12,402
Income tax expense	146	(641)	(57)	321	772	(380)	(792)	938	1,650	2,169
Net income from continuing operations	3,406	2,868	2,050	1,227	3,144	115	3,293	5,961	7,041	10,233
Net income	3,499	3,001	2,155	1,335	3,196	112	3,288	5,955	7,035	10,225
Net income to common shareholders	3,499	3,001	2,155	1,335	3,196	112	3,288	5,955	7,035	10,225